ProCE Banner Activity

Retrospective Analysis of Ibrutinib Discontinuation and Outcomes in CLL in Trial vs Real-World Settings

Slideset Download
Conference Coverage
In this study, median PFS with ibrutinib was similar in the clinical trial and real-world settings, although more patients discontinued for treatment-related adverse events in the real-world setting.

Released: December 05, 2016

Expiration: December 04, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen